Crescita Therapeutics Inc.
CTX.TO
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 23.55% | 16.96% | -1.99% | 9.86% | -8.23% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 23.55% | 16.96% | -1.99% | 9.86% | -8.23% |
| Cost of Revenue | 33.99% | 23.63% | 12.71% | 36.76% | 0.47% |
| Gross Profit | 15.20% | 11.42% | -13.54% | -8.74% | -14.17% |
| SG&A Expenses | -6.89% | -2.55% | -1.47% | 4.05% | 2.32% |
| Depreciation & Amortization | 2.50% | -7.20% | -14.83% | -10.64% | -8.97% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.66% | 6.52% | 2.48% | 14.47% | 1.00% |
| Operating Income | 76.11% | 47.12% | -35.10% | -55.64% | -136.37% |
| Income Before Tax | 118.67% | 53.55% | -44.96% | -77.70% | -189.59% |
| Income Tax Expenses | -106.91% | -106.91% | -104.67% | -102.97% | 199.52% |
| Earnings from Continuing Operations | 117.82% | 57.05% | -26.55% | -36.50% | -303.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 117.82% | 57.05% | -26.55% | -36.50% | -303.07% |
| EBIT | 76.11% | 47.12% | -35.10% | -55.64% | -136.37% |
| EBITDA | 131.41% | 73.34% | -106.09% | -227.10% | -1,616.80% |
| EPS Basic | 118.67% | 55.73% | -32.41% | -43.25% | -322.04% |
| Normalized Basic EPS | 131.71% | 52.41% | -52.56% | -90.32% | -215.34% |
| EPS Diluted | 116.60% | 55.57% | -32.08% | -42.65% | -335.10% |
| Normalized Diluted EPS | 131.54% | 52.26% | -52.56% | -90.32% | -212.04% |
| Average Basic Shares Outstanding | -3.03% | -3.82% | -4.25% | -4.44% | -3.85% |
| Average Diluted Shares Outstanding | -2.88% | -3.69% | -4.25% | -4.44% | -4.14% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |